INGREDIENTS & RESEARCH

Cholesstrinol HP™

BACKGROUND

Ingredient Type: Constituent, Concentrate, Extract, Metabolite

Also Known As: Flavoniod and tocotrienal blend

Cholesstrinol™ HP (High Potency) is a patented, clinically proven combination of citrus flavones and palm tocotrienols with eriocitrin. 

HP synergistically supports the body's natural promotion of healthy cholesterol and triglyceride levels by utilizing multiple mechanisms and bio-pathways.  Additionally, Cholesstrinol™ HP provides powerful antioxidant effects while promoting the body’s natural anti-inflammatory response (3).

 

TRADITIONAL USES

  • To maintain cholesterol and triglyceride levels already within the normal range
  • To support healthy inflammatory response
  • To support improvements in CRP (C reactive protein) marker level and thereby reduce inflammation and improve cardiovascular health

 

WHAT DOES SCIENCE TELL US?

An open-label study of the Cholesstrinol™HP formulation indicated that it could reduce high-sensitivity C-reactive protein (hsCRP), a marker of inflammation associated with increased risk of cardiovascular disease (CVD).  The study, conducted by Dr. Andreas Biller and team from Dr. Loges and company in Germany, involved hypercholesterolemic men and women (n=84) who received the Cholesstrinol HP formula for 12 weeks.  At the end of the intervention, the subjects taking Cholesstrinol HP had an average 42% reduction in hsCRP levels from 2.4 mg/L to 1.4 mg/L.  Among subjects considered as best responders, hsCRP levels dropped from 3.6 mg/L to 1.7 mg/L, a 57% decrease (1).

There are also several studies that investigated combined citrus flavones and palm tocotrienols branded Sytrinol®. The largest study, a 12-week double-blind, placebo-controlled protocol with 120 subjects, resulted in significant improvements in total cholesterol (-30%), LDL (-27%), and triglycerides (-34%), compared to placebo.  In addition, HDL levels increased 4%, resulting in a significant 29% improvement in the LDL:HDL ratio (2).

 

SAFETY

No known reported adverse events.

 

REFERENCES

  1. The “Jupiter Study,” published in the New England Journal of Medicine(2008;359:2195-207)
  2. Alternative Therapies in Health and Medicine (November/December 2007, Vol. 13, No. 6)
  3. https://www.nutraingredients-usa.com/Article/2012/10/25/SourceOne-unveils-concentrated-citrius-flavones-palm-tocotrienols-formulas

See Source One's webpage about their Cholesstrinol™ products for more information.